AstraZeneca PLC Files 6-K Report

TL;DR

AZN filed a 6-K, important notice for investors, check Form 20-F.

AI Summary

AstraZeneca PLC filed a Form 6-K on September 29, 2025, to report information as a foreign private issuer. The filing indicates that AstraZeneca is required to file annual reports under Form 20-F. The document is important and requires immediate attention, recommending recipients seek financial advice if in doubt.

Why It Matters

This filing serves as an official notification to the SEC and investors about AstraZeneca's reporting status and the importance of the document for understanding the company's ongoing disclosures.

Risk Assessment

Risk Level: low — This is a routine administrative filing by a large, established company and does not contain specific financial or operational news that would typically increase risk.

Key Players & Entities

• AstraZeneca PLC (company) — Filer of the report
• SEC (company) — Recipient of the filing
• Form 6-K (document) — Type of filing
• Form 20-F (document) — Annual report form

FAQ

Key Financial Figures

• $24.7b — ity. Total Revenue has increased from $24.7bn in 2015 to $54.1bn in 2024 and Core Op
• $54.1b — e has increased from $24.7bn in 2015 to $54.1bn in 2024 and Core Operating Profit from
• $6.9b — in 2024 and Core Operating Profit from $6.9bn to $16.9bn. Annual core R&D spending i
• $16.9b — nd Core Operating Profit from $6.9bn to $16.9bn. Annual core R&D spending increased fr
• $5.6b — Annual core R&D spending increased from $5.6bn to $12.2bn over the same period. A s
• $12.2b — e R&D spending increased from $5.6bn to $12.2bn over the same period. A significant

Filing Documents

• tm2526326-11_6k.htm (6-K) — 661KB
• lg_astrazeneca-4c.jpg (GRAPHIC) — 15KB
• lg_computershare-bw.jpg (GRAPHIC) — 8KB
• sg_matthewbowden-bw.jpg (GRAPHIC) — 6KB
• sg_micheldemare-bw.jpg (GRAPHIC) — 12KB
• 0001104659-25-094039.txt ( ) — 720KB

LETTER FROM THE CHAIR OF A straZeneca PLC

PART I LETTER FROM THE CHAIR OF A straZeneca PLC 7

EXPLANATION OF THE PROPOSALS TO IMPLEMENT THE HARMONISED LISTING STRUCTURE

PART II EXPLANATION OF THE PROPOSALS TO IMPLEMENT THE HARMONISED LISTING STRUCTURE 9

SETTLEMENT AND DEALINGS IN A straZeneca SHARES FOLLOWING THE SETTLEMENT SYSTEM MIGRATION

PART III SETTLEMENT AND DEALINGS IN A straZeneca SHARES FOLLOWING THE SETTLEMENT SYSTEM MIGRATION 14

CERTAIN TAXATION MATTERS

PART IV CERTAIN TAXATION MATTERS 21

PROPOSED AMENDMENTS TO THE EXISTING ARTICLES

PART V PROPOSED AMENDMENTS TO THE EXISTING ARTICLES 25

DEFINITIONS

PART VI DEFINITIONS 28

NOTICE OF GENERAL MEETING

PART VII NOTICE OF GENERAL MEETING 33 1 TABLE OF CONTENTS EXPECTED TIMETABLE OF PRINCIPAL EVENTS Event Expected time/date (1) Publication of this Circular 29 September 2025 Posting of this Circular and Notice of General Meeting, the Forms of Proxy, CSN voting forms and voting instruction cards 30 September 2025 Latest time and date for receipt of Forms of Proxy, online proxy appointments and CREST electronic proxy appointment instruction 2:30 p.m. (GMT) on 30 October 2025 (2) Voting Record Time for the General Meeting 6:30 p.m. (GMT) on 30 October 2025 (3) General Meeting 2:30 p.m. (GMT) on 3 November 2025 The following dates are indicative only and subject to change Expected date for termination of ADR Programme, delisting of AstraZeneca ADSs and cancellation of the listing and trading of AstraZeneca US Bonds on Nasdaq 2 February 2026 Expected time and date for commencement of trading in AstraZeneca Shares and AstraZeneca US Bonds on the NYSE By 8:00 a.m. (ET) on 2 February 2026 Expected date for the issuance of AstraZeneca DIs to relevant CREST participant accounts On or around 2 February 2026 Expected date for the issuance of statements of entitlement for existing CSN Eligible Certificated Shareholders and CSN Participants By no later than 16 February 2026 NOTES: (1) All dates and times are based on AstraZeneca's current expectations and are subject to change. If any of the dates and/or times change, AstraZeneca will give notice of the change by issuing an announcement through a Regulatory News Service. (2) Note that different deadlines apply to holders of Swedish Listed Shares and AstraZeneca ADSs and to existing CSN Participants, who should refer instead to the Notes to the Notice of General Meeting included in this document and any other documentation made available to them. In the event that the General Meeting is adjourned, not later than 48 hours (excluding any part of any day that is a non

Forward-looking statements

Forward-looking statements This document contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group, including, among other things, statements about expected revenues, margins, earnings per share or other financial or other measures. Although the Group believes its expectations are based on reasonable assumptions, any forward-looking statements, by their very nature, involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted. The forward-looking statements reflect knowledge and information available at the date of preparation of this document and the Group undertakes no obligation to update these forward-looking statements. The Group identifies the forward-looking statements by using the words anticipates', believes', expects', intends' and similar expressions in such statements. Important factors that could cause actual results to differ materially from those contained in forward-looking statements, certain of which are beyond the Group's control, include, among other things: 1. the risk of failure or delay in delivery of pipeline or launch of new medicines; 2. the risk of failure to meet regulatory or ethical requirements for medicine development or approval; 3. the risk of failures or delays in the quality or execution of the Group's commercial strategies; 4. the risk of pricing, affordability, access and competitive pressures; 5. the risk of failure to maintain supply of compliant, quality medicines; 6. the risk of illegal trade in the Group's medicines; 7. the impact of reliance on third-party goods and services; 8. the risk of failure in information technology or cybersecurity; 9. the risk of failure of critical processes; 10. the risk of failure to collect and manage data and artificial intelligence in line with legal and regulatory requirements and strate

View Full Filing

View this 6-K filing on SEC EDGAR